AJOVY is available in an autoinjector. Learn more

You had searched for:

There were no results matching the query.

You can also browse the topics below to find what you are looking for.

Patient Profiles


Maura

Anna

Need help answering a question?

Support Services

  1. Download the Prescription and Service Request Form (PSRF)
  2. Fax the completed form to Shared Solutions® at 1-844-257-6127

Patients can call 1-800-887-8100, Monday–Friday, 8 am–6 pm CT.

Maura Chronic migraine patient

  • Maura feels her migraine affects her family

  • She is regularly using acute medication to treat her migraine attacks

  • As a mom with a busy lifestyle, Maura wants the flexibility to choose a dosing option

" Is AJOVY right for me? "

 

Significantly more migraine-free days with AJOVY vs placebo1

In chronic migraine, a reduction in monthly headache days of at least moderate severity was demonstrated during the 12-week period (primary endpoint), with results seen as early as week 11,2

  • Patients with a mean baseline of 12.8 headache days of at least moderate severity per month experienced 4.6 fewer headache days per month, on average, with monthly dosing (vs 2.5 with placebo)1*

Significant reduction in the use of acute medication vs placebo1

Chronic migraine patients with a mean baseline of 13.1 days of acute medication use per month saw an average reduction of 4.2 days with monthly dosing vs 1.9 days with placebo (secondary endpoint)1,2*

SEE EFFICACY DATA FOR AJOVY

AJOVY is the only anti-CGRP injection with the option of dosing just 4 times a year

Quarterly dosing option for AJOVY

Only 4 injection days per year with quarterly dosing 675 mg SC

AJOVY can also be administered monthly 225 mg SC

  • Administration at home by a patient or caregiver or in office by a healthcare professional
    • Guidance on proper subcutaneous administration techniques should be provided
  • The most common adverse reactions (≥5% and greater than placebo) were injection-site reactions1

SEE DOSING FOR AJOVY

Study design1-3

AJOVY was evaluated in three phase 3, 12-week, randomized, double-blind, placebo-controlled, parallel-group trials, and a long-term extension study.

  • In the HALO Chronic migraine trial, the primary endpoint, for both quarterly and monthly dosing, was the mean change from baseline in the monthly average number of headache days of at least moderate severity during the 12-week period

SEE STUDY DESIGNS

*P<0.001.1 Patients with a mean baseline of 13.2 headache days of at least moderate severity per month experienced 4.3 fewer headache days per month, on average, with quarterly dosing vs 2.5 days with placebo, P<0.001.1 Reduction of acute medication use (secondary endpoint): patients in the chronic migraine trial with a mean baseline of 13.1 days for quarterly dosing and 13.0 days for placebo saw a mean reduction of 3.7 days for quarterly dosing vs 1.9 days with placebo, P<0.001.1,2

Suggestions to explore next

Continue to AJOVY Efficacy page

AJOVY helped significantly reduced monthly migraine days vs. Placebo1

SEE THE CLINICAL TRIAL DATA FOR AJOVY

Only 4 injection days per year with quarterly dosing

Dosing for AJOVY
Continue to AJOVY Safety page

Safety profile in clinical trials for AJOVY1

safety profile for ajovy